Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review

References

• Lewis DB. Avian flu to human influenza. Annu Rev Med 2006; 57:139-54; PMID:16409141; http://dx.doi.org/10.1146/annurev.med.57.121304.131333
   PubMed Web of Science ®Google Scholar
• De Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W. Economic value of influenza vaccination. Hum Vaccin Immunother 2012; 8:78-88; http://dx.doi.org/10.4161/hv.8.1.18420
   Web of Science ®Google Scholar
• Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974–76. N Engl J Med 1978; 298:587-92; PMID:628375; http://dx.doi.org/10.1056/NEJM197803162981103
   PubMed Web of Science ®Google Scholar
• Ruf BR, Knuf M. The burden of seasonal and pandemic influenza in infants and children. Eur J Pediatr 2014; 173:265-76; PMID:23661234; http://dx.doi.org/10.1007/s00431-013-2023-6
   PubMed Web of Science ®Google Scholar
• Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9; PMID:17006279; http://dx.doi.org/10.1097/01.inf.0000237829.66310.85
   PubMed Web of Science ®Google Scholar
• Baguelin M, Van Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ. Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation. Vaccine 2010; 28:2370-84; PMID:20096762; http://dx.doi.org/10.1016/j.vaccine.2010.01.002
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine 2012; 30:886-92; PMID:22155144; http://dx.doi.org/10.1016/j.vaccine.2011.11.104
   PubMed Web of Science ®Google Scholar
• Nichol KL. Cost-effectiveness and socio-economic aspects of childhood influenza vaccination. Vaccine 2011; 29:7554-8; PMID:21820477; http://dx.doi.org/10.1016/j.vaccine.2011.08.015
   PubMed Web of Science ®Google Scholar
• Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine 2013; 31:927-42; PMID:23246550; http://dx.doi.org/10.1016/j.vaccine.2012.12.010
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy T V, Cortese M, Rodewald L. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics 2014; 133:577-85; PMID:24590750; http://dx.doi.org/10.1542/peds.2013-0698
   PubMed Web of Science ®Google Scholar
• Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001; 108:E24; PMID:11483834; http://dx.doi.org/10.1542/peds.108.2.e24
   PubMedGoogle Scholar
• Marchetti M, Kühnel UM, Colombo GL, Esposito S, Principi N. Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin 2007; 3:14-22; PMID:17245134; http://dx.doi.org/10.4161/hv.3.1.3657
   PubMed Web of Science ®Google Scholar
• Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine 2007; 25:8010-20; PMID:17936446; http://dx.doi.org/10.1016/j.vaccine.2007.09.018
   PubMed Web of Science ®Google Scholar
• Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001; 33:1879-85; PMID:11692300; http://dx.doi.org/10.1086/324491
   PubMed Web of Science ®Google Scholar
• Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI. Cost-effectiveness of 2009 Pandemic influenza A(H1N1) vaccination in the United States. PLoS One 2011; 6:e22308
   PubMed Web of Science ®Google Scholar
• Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, Lieu TA. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med 2011; 165:112-8; PMID:20921341; http://dx.doi.org/10.1001/archpediat-rics.2010.182
   PubMedGoogle Scholar
• Lugner AK, van Boven M, de Vries R, Postma MJ, Wallinga J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. Bmj 2012; 345:e4445-e4445; PMID:22791791; http://dx.doi.org/10.1136/bmj.e4445
   PubMedGoogle Scholar
• Sanders GD, Taira A V. Cost effectiveness of a potential vaccine for Human papillomavirus. Emerg Infect Dis 2003; 9:37-48; PMID:12533280; http://dx.doi.org/10.3201/eid0901.020168
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769; PMID:18640957; http://dx.doi.org/10.1136/bmj.a769
   PubMed Web of Science ®Google Scholar
• Insinga R, Allen S, Carides G, Myers E. Reductions in human papillomavirus-disease resource use and costs with quadrivalent vaccination: The FUTURE study economic evaluation. Value Heal 2008; in press 11(7):1022-32; http://dx.doi.org/10.1111/j.1524-4733.2008.00342.x
   PubMed Web of Science ®Google Scholar
• Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100:308-20; PMID:18314477; http://dx.doi.org/10.1093/jnci/djn019
   PubMed Web of Science ®Google Scholar
• Chesson HW. Cost-Effectiveness of Human Papillomavirus Vaccination in the United States. Emerg Infect Dis 2008; 14:244-51; PMID:18258117; http://dx.doi.org/10.3201/eid1402.070499
   PubMed Web of Science ®Google Scholar
• Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008; 24:10-9; PMID:18218164; http://dx.doi.org/10.1017/S0266462307080026
   PubMed Web of Science ®Google Scholar
• Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009; 112:370-6; PMID:19041125; http://dx.doi.org/10.1016/j.ygyno.2008.09.031
   PubMed Web of Science ®Google Scholar
• Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, Büsch K. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health (Bangkok) 2009; 17:77-86; http://dx.doi.org/10.1007/s10389-008-0228-3
   Google Scholar
• Diaz M, De Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010; 46:2973-85; PMID:20638840; http://dx.doi.org/10.1016/j.ejca.2010.06.016
   PubMed Web of Science ®Google Scholar
• Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Bmj 2011; 343:d5775-d5775; PMID:21951758; http://dx.doi.org/10.1136/bmj.d5775
   PubMed Web of Science ®Google Scholar
• Melliez H, Levybruhl D, Boelle PY, Dervaux B, Baron S, Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26:706-15; PMID:18166250; http://dx.doi.org/10.1016/j.vaccine.2007.11.064
   PubMed Web of Science ®Google Scholar
• Jit M, Bilcke J, Mangen M-JJ, Salo H, Melliez H, Edmunds WJ, Yazdan Y, Beutels P. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27:6121-8; PMID:19715781; http://dx.doi.org/10.1016/j.vaccine.2009.08.030
   PubMed Web of Science ®Google Scholar
• Giammanco MD, Coniglio MA, Pignato S, Giammanco G. An economic analysis of rotavirus vaccination in Italy. Vaccine 2009; 27:3904-11; PMID:19446934; http://dx.doi.org/10.1016/j.vaccine.2009.04.002
   PubMed Web of Science ®Google Scholar
• Panatto D, Amicizia D, Ansaldi F, Marocco A, Marchetti F, Bamfi F, Giacchino R, Tacchella A, Del Buono S, Gasparini R. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine 2009; 27:3450-3; PMID:19200850; http://dx.doi.org/10.1016/j.vaccine.2009.01.054
   PubMed Web of Science ®Google Scholar
• Martin A, Batty A, Roberts JA, Standaert B. Cost-effectiveness of infant vaccination with RIX4414 (RotarixTM) in the UK. Vaccine 2009; 27:4520-8; PMID:19446594; http://dx.doi.org/10.1016/j.vaccine.2009.05.006
   PubMed Web of Science ®Google Scholar
• Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27:4025-30; PMID:19389452; http://dx.doi.org/10.1016/j.vaccine.2009.04.030
   PubMed Web of Science ®Google Scholar
• Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine 2012; 30:6766-76; PMID:23000223; http://dx.doi.org/10.1016/j.vaccine.2012.09.025
   PubMed Web of Science ®Google Scholar
• Knoll S, Mair C, Benter U, Vouk K, Standaert B. Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany? Health Econ Rev 2013; 3:27; PMID:24246029; http://dx.doi.org/10.1186/2191-1991-3-27
   PubMedGoogle Scholar
• Imaz I, Rubio B, Cornejo AM, González-Enríquez J. Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain. Prev Med (Baltim) 2014; 61:116-21; http://dx.doi.org/10.1016/j.ypmed.2013.12.013
   PubMed Web of Science ®Google Scholar
• Aidelsburger P, Grabein K, Böhm K, Dietl M, Wasem J, Koch J, Ultsch B, Weidemann F, Wichmann O. Cost-effectiveness of childhood rotavirus vaccination in Germany. Vaccine 2014; 32:1964-74; PMID:24561052; http://dx.doi.org/10.1016/j.vaccine.2014.01.061
   PubMed Web of Science ®Google Scholar
• Szucs T. Cost-effectiveness of hepatitis A and B vaccination programme in Germany. Vaccine 2000; 18:S86-9; PMID:10683559; http://dx.doi.org/10.1016/S0264-410X(99)00474-0
   PubMedGoogle Scholar
• Siddiqui MR, Gay N, Edmunds WJ, Ramsay M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine 2011; 29:466-75; PMID:21073988; http://dx.doi.org/10.1016/j.vaccine.2010.10.075
   PubMed Web of Science ®Google Scholar
• Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D, Bonanni P. Economic analysis of the first 20 y of universal hepatitis B vaccination program in Italy: An a posteriori evaluation and forecast of future benefits. Hum Vaccines Immunother 2013; 9:1119-28; http://dx.doi.org/10.4161/hv.23827
   PubMed Web of Science ®Google Scholar
• Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002; 324:809; PMID:11934772; http://dx.doi.org/10.1136/bmj.324.7341.809
   PubMed Web of Science ®Google Scholar
• Ortega-Sanchez IR, Lee GM, Jacobs RJ, Prosser LA, Molinari N-A, Zhang X, Baine WB, McCauley MM, Miller T. Projected cost-effectiveness of new vaccines for adolescents in the United States. Pediatrics 2008; 121 Suppl:S63-78; PMID:18174323; http://dx.doi.org/10.1542/peds.2007-1115H
   PubMedGoogle Scholar
• Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. Bmj 2014; 349:g5725-g5725; PMID:25301037; http://dx.doi.org/10.1136/bmj.g5725
   PubMed Web of Science ®Google Scholar
• Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine 2013; 31:2638-46; PMID:23566946; http://dx.doi.org/10.1016/j.vaccine.2013.03.034
   PubMed Web of Science ®Google Scholar
• Claes C, Graf Von Der Schulenburg JM. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 2003; 21:587-600; PMID:12751916; http://dx.doi.org/10.2165/00019053-200321080-00005
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004; 22:4203-14; PMID:15474710; http://dx.doi.org/10.1016/j.vaccine.2004.05.003
   PubMed Web of Science ®Google Scholar
• Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006; 25:494-501; PMID:16732146; http://dx.doi.org/10.1097/01.inf.0000222403.42974.8b
   PubMed Web of Science ®Google Scholar
• Lieu T a, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, Miller MA, Shinefield HR. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000; 283:1460-8; PMID:10732936; http://dx.doi.org/10.1001/jama.283.11.1460
   PubMed Web of Science ®Google Scholar
• Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: Considering a high-risk population and herd immunity effects. Eur J Heal Econ 2008; 9:7-15; http://dx.doi.org/10.1007/s10198-006-0013-6
   PubMed Web of Science ®Google Scholar
• Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR. Cost-effectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States. Vaccine 2009; 27:6483-94; PMID:19720366; http://dx.doi.org/10.1016/j.vaccine.2009.08.045
   PubMed Web of Science ®Google Scholar
• Giorgi-Rossi P, Merito M, Borgia P. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy. Health Policy (New York) 2009; 89:225-38; http://dx.doi.org/10.1016/j.healthpol.2008.05.016
   PubMed Web of Science ®Google Scholar
• Claes C, Reinert RR, Von Der Schulenburg JMG. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Heal Econ 2009; 10:25-38; http://dx.doi.org/10.1007/s10198-008-0098-1
   PubMed Web of Science ®Google Scholar
• Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá J, Lluch-Rodrigo JA, Pastor-Villalba E. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine 2011; 29:9640-8; http://dx.doi.org/10.1016/j.vaccine.2011.10.038
   PubMed Web of Science ®Google Scholar
• Thiry N, Beutels P, Tancredi F, Roman∫ L, Zanetti A, Bonanni P, Gabutti G, Van Damme P. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004; 22:3546-62; PMID:15315834; http://dx.doi.org/10.1016/j.vaccine.2004.03.043
   PubMed Web of Science ®Google Scholar
• Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain-Results from a dynamic model. Vaccine 2006; 24:6980-9; PMID:16860909; http://dx.doi.org/10.1016/j.vaccine.2006.04.051
   PubMed Web of Science ®Google Scholar
• Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Heal 2005; 8:209-22; http://dx.doi.org/10.1111/j.1524-4733.2005.04005.x
   PubMed Web of Science ®Google Scholar
• Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis 2008; 197 Suppl:S156-64; PMID:18419391; http://dx.doi.org/10.1086/522135
   PubMedGoogle Scholar
• Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996 [cited 2015 May 29]; 313:275-83; PMID:8704542; http://dx.doi.org/10.1136/bmj.313.7052.275
   PubMed Web of Science ®Google Scholar
• WHO. Vaccine Introduction Guidelines: Adding a vaccine to a national immunization programme: decision and implementation. 2005.
   Google Scholar
• Walker D, Beutels P. WHO guide for standardization of economic evaluations of immunization programmes: Immunization , Vaccines and Biologicals. Vaccine 2008; 28:1-116
   Web of Science ®Google Scholar
• Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008 [cited 2015 Sep 15]; 8:727-33; PMID:18992409; http://dx.doi.org/10.1016/S1473-3099(08)70258-5
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. The role of season in the epidemiology of influenza. J Hyg (Lond) 1981 [cited 2015 Sep 15]; 86:35-47; PMID:7462597; http://dx.doi.org/10.1017/S0022172400068728
   PubMedGoogle Scholar
• Bin-Chia Wu D, Chaiyakunapruk N, Chong H-Y, Beutels P. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006-2014). Vaccine 2015 [cited 2015 Feb 19]; 33:1633-58; PMID:25681663; http://dx.doi.org/10.1016/j.vaccine.2015.01.081
   PubMed Web of Science ®Google Scholar
• Boccalini S, Azzari C, Resti M, Valleriani C, Cortimiglia M, Tiscione E, Bechini A, Bonanni P. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine 2011; 29:9521-8; PMID:22008820; http://dx.doi.org/10.1016/j.vaccine.2011.10.013
   PubMed Web of Science ®Google Scholar
• Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007; 54:530-8; PMID:17097147; http://dx.doi.org/10.1016/j.jinf.2006.09.017
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Ioannidis JP a, Clarke M, Devereaux PJ, Kleijnen J, Moher D. Annals of Internal Medicine Academia and Clinic The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Ann Intern Med 2009; 151:W65-94; PMID:19622512; http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00136
   PubMed Web of Science ®Google Scholar
• MEPS. Medical Expenditure Panel Survey;
   Google Scholar
• XE. XE Currency Converter
   Google Scholar
• European Central Bank. Health
   Google Scholar
• Joint Committee on Vaccination and Immunisation. Code of Practice June 2013. 2013;
   Google Scholar